Savitr Capital

Immunis.AI operates a liquid biopsy platform called Intelligentia, which provides diagnostic insights to physicians for personalized patient treatment. The platform uses individualized multi-omics profiling to address various indications in oncology, metabolic, autoimmune, and neurodegenerative diseases.

Fidelis Pharmaceuticals offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs. Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor. The company is headquartered in North Brunswick, New Jersey.

Glytec is a medical software company that provides cloud-based insulin management and glycemic control solutions for diabetes care in hospitals and at home. Its flagship platform, the eGlycemic Management System (eGMS), delivers decision support and real-time insights to optimize insulin therapy and reduce hyperglycemia and hypoglycemia. The suite includes Glucommander for individualized IV and subcutaneous insulin dosing, GlucoSurveillance for real-time glycemic monitoring, GlucoMetrics for analytics on hospital glycemic control, and SmartClick access to core applications from electronic medical records. It also offers Hospital-to-Home Discharge Recommendations that guide post-discharge regimens based on patient data. The company combines FDA-cleared software with evidence-based clinical services to improve patient safety, lower readmissions, and reduce waste associated with insulin therapy, serving providers, payers, and patients worldwide. Glytec is headquartered in Massachusetts with an additional office in South Carolina.

Biora Therapeutics is a biotechnology company focused on developing innovative oral biotherapeutics that combine drug and device technologies. The company's primary aim is to enhance treatment approaches for patients by enabling targeted delivery of therapeutics directly to the gastrointestinal tract, particularly for conditions such as Inflammatory Bowel Disease (IBD). Additionally, Biora Therapeutics is working on systemic delivery methods that replace traditional injection techniques with needle-free, oral delivery systems. By advancing these biotherapeutic solutions, Biora Therapeutics seeks to improve patient outcomes and streamline the administration of medications, making treatments more accessible and effective.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

BioIQ, founded in 2005 and based in Atlanta, Georgia, is a health improvement technology company focused on enhancing corporate health and wellness programs. It offers a unique health screening platform and an ecosystem of tools designed to provide quantifiable wellness insights. BioIQ's solutions include humanized analytics, omnichannel communications, and care navigation services for health plans, employers, and government entities. The company collaborates with major employers and health companies across the United States, having successfully launched over 3,000 health improvement programs.

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, They have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of their pipeline.

Ancora Heart is a medical device company focused on improving the quality of life and longevity for individuals suffering from heart failure. The company has developed the AccuCinch System, an investigational therapy aimed at repairing the enlarged left ventricle, which is a primary factor in heart failure. This innovative treatment addresses the underlying dysfunction of the left ventricle, providing a minimally invasive option for millions of patients who lack effective alternatives. The AccuCinch System not only reduces the size of the ventricle but also supports and strengthens the heart wall, helping patients manage symptoms such as extreme fatigue, difficulty breathing, and memory loss. Through its advancements, Ancora Heart aims to transform heart failure management and enhance patient well-being.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Svelte Medical Systems, founded in 2007 by Robert Fischell, David Fischell, and Tim Fischell, specializes in the design, development, and commercialization of balloon-expandable stents for treating atherosclerosis via percutaneous coronary intervention (PCI). The company offers two primary products: SLENDER Integrated Delivery System (IDS), a drug-eluting stent-on-a-wire system that facilitates transradial interventions by downsizing catheters; and DIRECT Rapid Exchange System (RX), a drug-eluting stent designed to enhance direct stenting and high-pressure post-dilatations. Svelte aims to improve stent deliverability, reduce costs, and enhance safety compared to existing market products in the $5 billion coronary stent market.

Vascular Therapies, Inc. is a biopharmaceutical company based in Cresskill, New Jersey, founded in 2001, that focuses on developing innovative treatments for patients requiring vascular access for hemodialysis. The company's primary product candidate, which includes sirolimus, has received orphan drug designations in both the United States and the European Union for its applications in dialysis vascular access. Vascular Therapies is dedicated to addressing significant unmet clinical needs, particularly concerning arteriovenous fistula creation, and offers biodegradable collagen implants aimed at reducing vascular anastomosis failure. Through its advancements, the company seeks to enhance clinical outcomes for patients undergoing dialysis and improve their quality of life.